Professor Jean-Yves Blay, MD is a medical oncologist, General Director of the Centre Leon Berard, the Comprehensive Cancer Centre of Lyon France, researcher and a Professor at the University Claude Berard, France. Since 2019, he is the President of the French Federation of Cancer Centers Unicancer.
His work focuses on sarcoma, genomics and targeted treatment of cancer, immune-oncology, and the relationship between tumour immunologic microenvironment and malignant cells, with the goal of clinical applications in the field of diagnosis, prognosis and treatment.
He has been distinguished with the Hamilton-Fairly award from ESMO (2012) and the Henry and Mary-Jane Mitjaville prize from the National Academy of Medicine (2013).
Professor Blay is the Subject Editor for Sarcoma and Gastrointestinal Stromal Tumors for the ESMO Guidelines Committee, and the Director of ERN-EURACAN, designated by the EU Commission in 2016 to improve the quality of care for patients with rare cancers in the European Union.
He is also the President of the French Sarcoma Group, the Network Leader of NETSARC sarcoma treatment reference centres, and a member of the ESMO EU Policy Committee and the ESMO Principles of Clinical Trials and Systematic Therapy Faculty.
Previously, he served as the President of EORTC between 2009 and 2012 and the former Principal Investigator of Conticanet, an EU Commission network of excellence.
Professor Blay has co-authored over 700 peer-reviewed articles and book chapters, and was distinguished as Highly Cited Researcher in 2019. He advises various national and international institutions and research organisations, and is an active member of several oncological organisations and societies, such as ESMO, ASCO and AACR.
17-Jun-2021FZ - InternationalThe elective care backlog: what can we learn from overseas?